​

Jasper Therapeutics (JSPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

JSPR Stock Forecast

Jasper Therapeutics (JSPR) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $55.50, with a high of $63.00 and a low of $48.00. This represents a 1297.98% increase from the last price of $3.97.

- $13 $26 $39 $52 $65 High: $63 Avg: $55.5 Low: $48 Last Closed Price: $3.97

JSPR Stock Rating

Jasper Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

JSPR Price Target Upside V Benchmarks

TypeNameUpside
StockJasper Therapeutics1297.98%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$58.67
Last Closing Price$3.97$3.97$3.97
Upside/Downside--1377.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2548---12
Mar, 2548---12
Feb, 2547---11
Jan, 2547---11
Dec, 2447---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 09, 2025Gregory RenzaRBC Capital$48.00$17.71171.03%1109.07%
Dec 05, 2024Etzer DaroutBMO Capital$63.00$21.53192.61%1486.90%
May 06, 2024Emily BodnarH.C. Wainwright$65.00$24.52165.09%1537.28%
Apr 03, 2024Gavin Clark-GartnerEvercore ISI$65.00$26.20148.09%1537.28%
Feb 07, 2023Cantor Fitzgerald$6.00$1.92212.50%51.13%
Jan 11, 2023Credit Suisse$3.00$1.6581.82%-24.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 09, 2025RBC CapitalOutperformOutperformhold
Jan 08, 2025BTIGBuyBuyhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 15, 2024H.C. WainwrightBuyBuyhold
Oct 14, 2024OppenheimerOutperformOutperformhold
Oct 14, 2024BTIGBuyBuyhold
Oct 14, 2024Cowen & Co.BuyBuyhold
Sep 09, 2024JMP SecuritiesOutperforminitialise
Aug 14, 2024RBC CapitalOutperformOutperformhold
Jul 08, 2024BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-10 $-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.18$-4.89----
Avg Forecast$-6.16$-4.55$-4.74$-5.01$-5.77$-5.79
High Forecast$-5.88$-4.30$-2.57$-3.56$-3.40$-5.79
Low Forecast$-6.37$-4.69$-7.01$-7.93$-9.50$-5.79
Surprise %0.32%7.47%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$4.40M$1.89M$10.71M$78.94M
High Forecast--$4.40M$1.89M$10.71M$78.94M
Low Forecast--$4.40M$1.89M$10.71M$78.94M
Surprise %------

Net Income Forecast

$-100M $-85M $-70M $-55M $-40M $-25M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-64.47M-----
Avg Forecast$-64.47M$-46.92M$-49.97M$-59.97M$-67.33M$-60.46M
High Forecast$-61.40M$-44.91M$-26.78M$-37.18M$-35.49M$-60.46M
Low Forecast$-66.52M$-48.93M$-73.15M$-82.76M$-99.17M$-60.46M
Surprise %------

JSPR Forecast FAQ

Is Jasper Therapeutics stock a buy?

Jasper Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jasper Therapeutics is a favorable investment for most analysts.

What is Jasper Therapeutics's price target?

Jasper Therapeutics's price target, set by 10 Wall Street analysts, averages $55.5 over the next 12 months. The price target range spans from $48 at the low end to $63 at the high end, suggesting a potential 1297.98% change from the previous closing price of $3.97.

How does Jasper Therapeutics stock forecast compare to its benchmarks?

Jasper Therapeutics's stock forecast shows a 1297.98% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Jasper Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Jasper Therapeutics’s EPS forecast?

Jasper Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.74, marking a -3.07% decrease from the reported $-4.89 in 2024. Estimates for the following years are $-5.01 in 2026, $-5.77 in 2027, and $-5.79 in 2028.

What is Jasper Therapeutics’s revenue forecast?

Jasper Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.4M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $1.89M, followed by $10.71M for 2027, and $78.94M for 2028.

What is Jasper Therapeutics’s net income forecast?

Jasper Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-49.965M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-59.97M in 2026, $-67.334M in 2027, and $-60.464M in 2028.